骨髓瘤骨病:骨髓瘤管理格局变化中持续存在的问题
多发性骨髓瘤患者因高效免疫介导抗骨髓瘤治疗的引入,新诊断和复发患者的结局显著改善,但骨髓瘤骨病仍显著增加发病率与死亡率。共识指南推荐常规纳入抗骨吸收治疗,但患者仍发生病理性骨折等骨相关事件。本综述讨论骨髓瘤骨病的诊断与发病机制、双膦酸盐指南推荐的证据基础,并探讨靶向成骨细胞活性、抗骨髓瘤治疗对骨病的影响及生物标志物指导骨靶向治疗强度与疗程的作用。
要点
- 共识指南推荐常规纳入抗骨吸收治疗,但患者仍发生病理性骨折等骨相关事件。
- 本综述讨论骨髓瘤骨病的诊断、发病机制及双膦酸盐指南推荐的证据基础。
- 探讨靶向成骨细胞活性、抗骨髓瘤治疗对骨病影响及生物标志物指导骨靶向治疗。
核心结论
- 尽管多发性骨髓瘤患者因高效免疫介导抗骨髓瘤治疗而生存期延长,骨髓瘤骨病仍显著贡献于发病率与死亡率。
- 共识指南推荐常规纳入抗骨吸收治疗,但患者仍持续发生病理性骨折等骨相关事件。
研究设计与样本
- 本文为综述,讨论骨髓瘤骨病的诊断与发病机制、双膦酸盐指南推荐的证据基础、靶向成骨细胞活性的新方法、抗骨髓瘤治疗对骨病的影响及生物标志物指导骨靶向治疗的作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes for patients with multiple myeloma have improved markedly in recent years due to the introduction of highly effective immune-mediated anti-myeloma therapies in both newly diagnosed and relapsed patients. Conversely, while patients are living longer, myeloma bone disease continues to contribute significantly to morbidity and mortality. Routine incorporation of anti-resorptive therapies into patient management is recommended by consensus guidelines; however, patients continue to sustain skeletal-related events, including pathological fractures. In this review, we discuss the diagnosis and pathogenesis of myeloma bone disease and the evidence underpinning guideline recommendations for the use of bisphosphonates in patients with myeloma. We consider novel approaches to reducing bone disease presented by targeting osteoblastic activity, the impact of anti-myeloma therapies themselves on bone disease and the role of biomarkers to monitor disease activity and guide the intensity and duration of bone-targeted therapy.
引用
- Swan D, Yong A, Vandyke K, et al. Myeloma bone disease: A constant problem in the changing landscape of myeloma management. Br J Haematol. 2025. PMID: 41178408. doi:10.1111/bjh.70240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。